Multivariable Cox regression of preplanned OS analysis
| Covariate . | HR (95% CI) . | P . |
|---|---|---|
| Treatment arm (venetoclax vs placebo) | 0.67 (0.47-0.96) | .03 |
| Age (<75 vs ≥75 y) | 0.56 (0.37-0.84) | .005 |
| AML status (de novo vs secondary) | 0.59 (0.41-0.85) | .004 |
| ECOG performance status (<2 vs ≥2) | 0.48 (0.33-0.70) | <.001 |
| Cytogenetic risk (intermediate vs poor) | 0.57 (0.40-0.82) | .003 |
| Covariate . | HR (95% CI) . | P . |
|---|---|---|
| Treatment arm (venetoclax vs placebo) | 0.67 (0.47-0.96) | .03 |
| Age (<75 vs ≥75 y) | 0.56 (0.37-0.84) | .005 |
| AML status (de novo vs secondary) | 0.59 (0.41-0.85) | .004 |
| ECOG performance status (<2 vs ≥2) | 0.48 (0.33-0.70) | <.001 |
| Cytogenetic risk (intermediate vs poor) | 0.57 (0.40-0.82) | .003 |